Retreatment with erlotinib in NSCLC harboring EGFR mutation ? case report.
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F12%3A%230000135" target="_blank" >RIV/26475821:_____/12:#0000135 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Retreatment with erlotinib in NSCLC harboring EGFR mutation ? case report.
Original language description
One of the modern therapeutic modalities in pneumooncology is a treatment using tyrosine kinase inhibitors to block the activation of epidermal growth factor receptor (EGFR) cascade. Erlotinib (Tarceva?) is an EGFR tyrosine kinase inhibitor, in clinicalpractice commonly used for treatment of advanced non-small cell lung carcinoma (NSCLC). Activating mutations of EGFR gene, deletion at the 19th exon and point mutations to 21 exon (L858) are universally considered as a good predictor of response to EGFR-TKI treatment.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NS9718" target="_blank" >NS9718: New possibilities for application of molecular-diagnostic methods for early detection and proper therapy selection of progressing Non-Small Cell Lung Cancer based on detection and monitoring of hypermethylation of specific genes</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů